Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders

Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders

Sponsors

Lead Sponsor: Mayo Clinic

Source Mayo Clinic
Brief Summary

The investigators aim to learn more about symptoms suggestive of a neurodegenerative process.

Detailed Description

The investigators will recruit participants with symptoms suggestive of a neurodegenerative and/or related disease. Participants could be evaluated on a yearly basis, undergoing a baseline visit and possible follow-up evaluations with an interval of one year. At each visit, participants could undergo any combination of the following based on their symptoms and complaints: a neurological assessment, a speech/language assessment, a neuropsychometric assessment, an MRI, an FDG PET/CT scan, a PiB PET/CT scan, a Tau PET/CT scan, a DaTscan, a gait lab test, an ocular motor or eye movement exam and/or a swallow evaluation. At baseline only, all participants will be asked to provide a blood sample to allow for future genetic studies.

Overall Status Recruiting
Start Date 2020-11-01
Completion Date 2050-11-01
Primary Completion Date 2050-11-01
Study Type Observational
Primary Outcome
Measure Time Frame
Imaging analysis 1 year
Enrollment 500
Condition
Intervention

Intervention Type: Drug

Intervention Name: C-11 PiB

Description: Completing PET scan looking for amyloid protein

Arm Group Label: Neurodegenerative symptoms

Intervention Type: Drug

Intervention Name: AV1451 Tau

Description: Completing PET scan looking for tau protein

Arm Group Label: Neurodegenerative symptoms

Eligibility

Sampling Method:

Non-Probability Sample

Criteria:

Inclusion Criteria: - All participants will be over the age of 21 - Have symptoms suggestive of a neurodegenerative and/or related disorder Exclusion Criteria: - Participants will be excluded if they have any concurrent illnesses that could account for all of their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes - Women that are pregnant or post-partum and breast-feeding will be excluded - Participants will be excluded if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, Hypogammaglobulinemia, Wiskott-Aldrich syndrome and Down's syndrome - Participants will be excluded from undergoing the MRI if it is contraindicated (metal in head, cardiac pace maker, etc), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts) - Participants will be excluded if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy)

Gender:

All

Minimum Age:

21 Years

Maximum Age:

N/A

Healthy Volunteers:

No

Overall Contact

Last Name: Sarah Boland, CCRP

Phone: 507-284-3863

Email: [email protected]

Location
Facility: Status: Contact: Mayo Clinic Sarah Boland, CCRP 507-284-3863 [email protected]
Location Countries

United States

Verification Date

2020-12-01

Responsible Party

Type: Principal Investigator

Investigator Affiliation: Mayo Clinic

Investigator Full Name: Keith A. Josephs

Investigator Title: Professor of Neurology

Has Expanded Access No
Condition Browse
Arm Group

Label: Neurodegenerative symptoms

Acronym AND1
Patient Data Undecided
Study Design Info

Observational Model: Cohort

Time Perspective: Prospective

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News